
Vaxcyte (PCVX) Stock Forecast & Price Target
Vaxcyte (PCVX) Analyst Ratings
Bulls say
Vaxcyte Inc. is positioned for potential substantial growth due to its promising product pipeline, particularly the VAX-31 vaccine, which is set to launch in 2028 and is projected to contribute significantly to a peak revenue estimate increase to $6.8 billion by 2040. The company has demonstrated strong Phase 1/2 clinical trial results, including meeting non-inferiority criteria against established vaccines, which could lead to positive regulatory outcomes and expanded market opportunities. Additionally, anticipated universal recommendations for PCV vaccinations among adults over 50 years old may further enhance the commercial landscape, increasing investor interest and providing momentum for the stock in the coming years.
Bears say
Vaxcyte Inc's stock outlook appears negative due to several fundamental risks, including potential delays in research and development, regulatory challenges, and disappointing clinical trial results that could hinder the commercial uptake of their vaccine candidates. The company's upcoming VAX-24 Phase 2 trial readout is anticipated with caution, as past investor expectations were not met, indicating a lack of confidence in achieving significant milestones in the highly competitive pediatric vaccine market. Moreover, the increasing scrutiny from regulatory bodies and the possibility that national vaccine guidelines may not endorse Vaxcyte's products further limit the company's commercial prospects.
This aggregate rating is based on analysts' research of Vaxcyte and is not a guaranteed prediction by Public.com or investment advice.
Vaxcyte (PCVX) Analyst Forecast & Price Prediction
Start investing in Vaxcyte (PCVX)
Order type
Buy in
Order amount
Est. shares
0 shares